Andrew is a European and UK Patent Attorney based in our London office. Having an educational background in both general chemistry and chemical physics, Andrew enjoys working with clients whose interests combine chemistry with other technical areas, such as petrochemical and biochemical engineering, electrochemistry, chemical modification of biological molecules including RNA therapeutics and antibodies, medical devices and computational chemistry. He has also worked extensively in the pharmaceutical field, including on commercially important patent portfolios relating to coeliac disease, antibody-based anti-cancer drugs and new delivery systems for local anaesthetics.
Andrew’s client base is extensive and diverse, but he has particular experience in advising companies based in the USA and Japan on their European IP strategy. Andrew also has extensive experience in prosecuting challenging US patent applications for domestic clients at the US PTO, with a strong track record of securing successful results against the odds. A regular visitor to the USA and Japan, Andrew keeps himself fully informed on legal developments in these commercially crucial jurisdictions.
Andrew advises many university-based technology transfer bodies, including UCL Business and Oxford University Innovation. He is known for providing easy-to-follow, pragmatic and commercially-minded advice to companies of all sizes on their IP strategy and portfolio management.
Andrew joined J A Kemp in 2006 and became a partner in 2016.
He is recommended by Who’s Who Legal: Patents and IAM Patent 1000. With IAM Patent 1000 commenting that “Andrew is the top European patent service provider working in his sphere. He treats the most valuable and difficult chemical cases with care. He is unfailingly prompt with advice and he can be counted on to guide clients through prosecution with an expert touch. Andrew is both an outstanding scientist and an outstanding patent practitioner – a rare and valuable combination. It is comforting to know that Andrew stands behind your patent strategy. His insight and perspective are greatly appreciated.”